🌕 Gate Square · Mid-Autumn Creator Incentive Program is Now Live!
Share your creations with trending topics and get a chance to split $5,000 in rewards! 🎁
👉 Join now: https://www.gate.com/campaigns/1953
💡 How to Join:
1️⃣ Post with the hashtag #Gate Square Mid Autumn Creator Incentive# .
2️⃣ Your content should follow the daily trending topics posted by [Gate _Square], and include both hashtags.
3️⃣ The more posts, higher quality, and greater engagement — the bigger your rewards! 🚀
💰 Creator Rewards:
🏆 Top 1: Bulgari Mid-Autumn Gift Box + $100 Futures Voucher + $100 GT
🥈 Top 2: Bulgari
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.